Free Trial
NASDAQ:SUPN

Supernus Pharmaceuticals (SUPN) Stock Price, News & Analysis

Supernus Pharmaceuticals logo
$32.41 -0.41 (-1.25%)
As of 10:57 AM Eastern

About Supernus Pharmaceuticals Stock (NASDAQ:SUPN)

Key Stats

Today's Range
$32.01
$32.62
50-Day Range
$31.17
$40.00
52-Week Range
$25.53
$40.28
Volume
60,276 shs
Average Volume
478,128 shs
Market Capitalization
$1.81 billion
P/E Ratio
30.29
Dividend Yield
N/A
Price Target
$36.00
Consensus Rating
Hold

Company Overview

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.

Remove Ads

Supernus Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
58th Percentile Overall Score

SUPN MarketRank™: 

Supernus Pharmaceuticals scored higher than 58% of companies evaluated by MarketBeat, and ranked 634th out of 927 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Supernus Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Supernus Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

  • Read more about Supernus Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Supernus Pharmaceuticals are expected to decrease by -39.50% in the coming year, from $2.38 to $1.44 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Supernus Pharmaceuticals is 30.29, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 21.95.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Supernus Pharmaceuticals is 30.29, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 22.79.

  • Price to Book Value per Share Ratio

    Supernus Pharmaceuticals has a P/B Ratio of 1.92. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Supernus Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    10.04% of the float of Supernus Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Supernus Pharmaceuticals has a short interest ratio ("days to cover") of 9.
  • Change versus previous month

    Short interest in Supernus Pharmaceuticals has recently decreased by 17.00%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Supernus Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Supernus Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    10.04% of the float of Supernus Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Supernus Pharmaceuticals has a short interest ratio ("days to cover") of 9.
  • Change versus previous month

    Short interest in Supernus Pharmaceuticals has recently decreased by 17.00%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Supernus Pharmaceuticals has a news sentiment score of 0.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 8 news articles for Supernus Pharmaceuticals this week, compared to 5 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Supernus Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $440,263.00 in company stock.

  • Percentage Held by Insiders

    Only 9.30% of the stock of Supernus Pharmaceuticals is held by insiders.

  • Read more about Supernus Pharmaceuticals' insider trading history.
Receive SUPN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Supernus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SUPN Stock News Headlines

Your Retirement Is Caught in the Crossfire
When Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. Now… as new tariffs take effect, gold is breaking records again. You've hopefully already seen this in action… but gold is surpassing $3,000 per ounce for the first time EVER.
See More Headlines

SUPN Stock Analysis - Frequently Asked Questions

Supernus Pharmaceuticals' stock was trading at $36.16 on January 1st, 2025. Since then, SUPN shares have decreased by 10.4% and is now trading at $32.41.
View the best growth stocks for 2025 here
.

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) issued its quarterly earnings data on Monday, November, 4th. The specialty pharmaceutical company reported $0.69 earnings per share for the quarter, topping the consensus estimate of $0.44 by $0.25. The firm's revenue for the quarter was up 14.2% on a year-over-year basis.

Shares of SUPN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Supernus Pharmaceuticals investors own include American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), DiamondRock Hospitality (DRH), The RMR Group (RMR), Humana (HUM) and AUO (AUOTY).

Company Calendar

Last Earnings
11/04/2024
Today
4/03/2025
Next Earnings (Estimated)
5/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:SUPN
Employees
580
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$36.00
High Stock Price Target
$36.00
Low Stock Price Target
$36.00
Potential Upside/Downside
+11.1%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

Trailing P/E Ratio
30.29
Forward P/E Ratio
13.62
P/E Growth
N/A
Net Income
$1.32 million
Pretax Margin
11.12%

Debt

Sales & Book Value

Annual Sales
$661.82 million
Cash Flow
$1.48 per share
Price / Cash Flow
21.83
Book Value
$16.87 per share
Price / Book
1.92

Miscellaneous

Free Float
50,084,000
Market Cap
$1.81 billion
Optionable
Optionable
Beta
0.84

Social Links

The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

This page (NASDAQ:SUPN) was last updated on 4/3/2025 by MarketBeat.com Staff
From Our Partners